title: A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer.
abstract: BACKGROUND
  The objective was to study the results of induction chemotherapy followed by external beam radiation therapy with concurrent cetuximab in the treatment of locally advanced head and neck cancer.
  
  
  METHODS
  Seventeen patients with stage III or IV squamous cell carcinomas of the head and neck who received docetaxel, cisplatinum, and 5-fluorouracil followed by radiation therapy with concurrent cetuximab were retrospectively analyzed. All radiation was delivered with image-guided intensity-modulated radiation treatments. Primary end points analyzed were local control and overall survival.
  
  
  RESULTS
  With a median follow-up of 17 months, the approximate 2-year local control was 85%, with overall survival being 91%. At time of last follow-up, only 1 death was observed, with the cause of death unknown. Two local failures were observed, and the patients were under active management for their recurrences at time of last follow-up. No distant metastatic failures were noted among the patients.
  
  
  CONCLUSIONS
  Induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiation with cetuximab provides for excellent locoregional control of disease. Future prospective studies can better establish the efficacy of this treatment regimen to current favored protocols.
authors.affiliation: Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA. bkim@hoaghospital.org
authors.forename: Brian
authors.initials: B
authors.lastname: Kim
authors.forename: Robert O
authors.initials: RO
authors.lastname: Dillman
authors.forename: Peter
authors.initials: P
authors.lastname: Chen
authors.forename: Russell
authors.initials: R
authors.lastname: Hafer
authors.forename: Craig
authors.initials: C
authors.lastname: Cox
authors.forename: Neil
authors.initials: N
authors.lastname: Barth
authors.forename: R Matthew
authors.initials: RM
authors.lastname: Carroll
authors.forename: Louis
authors.initials: L
authors.lastname: VanderMolen
authors.forename: Minh
authors.initials: M
authors.lastname: Nguyen
authors.forename: JinChu
authors.initials: J
authors.lastname: Huang
authors.forename: Annamarie
authors.initials: A
authors.lastname: Minion
authors.forename: Marianne
authors.initials: M
authors.lastname: Plunkett
authors.forename: Ralph
authors.initials: R
authors.lastname: Mackintosh
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068818:Cetuximab; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D008297:Male; D009367:Neoplasm Staging; D050397:Radiotherapy, Intensity-Modulated; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000077143:Docetaxel; D000068818:Cetuximab; D002945:Cisplatin; D005472:Fluorouracil